Spots Global Cancer Trial Database for Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
Official Title: An Open Label Multicentric Phase 1 Study of Selective Cyclin Dependent Kinase Inhibitor P276-00 in Patients With Advanced Refractory Neoplasms
Study ID: NCT00407498
Conditions
Interventions
Study Description
Brief Summary: P276-00 is specific Cdk4-D1 and Cdk1-B inhibitor. P276-00 exhibited significant tumour reduction in animal models with less adverse effects.Based on the results from various in-vitro studies, P276-00 could be a potential candidate as a new mechanism based drug for the treatment of cancer.This Phase I study will determine the Maximum Tolerated Dose,Dose Limiting Toxicity and efficacy of P 276-00 in patients with advanced Refractory neoplasms.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Juravinsky Cancer Centre, Hamilton, Ontario, Canada
Kingston General Hospital, Kingston, Ontario, Canada
Nizam's Institute of Medicai Sciences, Hyderabaad, Andhrapradesh, India
Contact Details
Name: Hal Hirte, MD, FRCP
Affiliation: Juravinsky Cancer Centre
Role: PRINCIPAL_INVESTIGATOR
Name: Tara Baetz, MD, FRCP
Affiliation: Queen's University
Role: PRINCIPAL_INVESTIGATOR
Name: Raghunadharao D, MD, DM
Affiliation: Nizam's Institute of Medicai Sciences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
